Rigosertib produces better OS in MDS than tAML

Print Friendly, PDF & Email


Micrograph showing
myelodysplastic syndrome
Rigosertib has demonstrated activity and tolerability in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia transformed from MDS (tAML), according to researchers. In a phase 1/2 study, rigosertib produced responses in a quarter of MDS/tAML patients and enabled stable disease in another quarter. Overall survival (OS) was about... [Read Article]
Print Friendly, PDF & Email

Generic azacitidine approved in Canada

Print Friendly, PDF & Email


Micrograph showing
acute myeloid leukemia
Health Canada has approved Dr. Reddy’s Laboratories Ltd.’s Azacitidine for Injection 100 mg/vial, a bioequivalent generic version of VIDAZA® (azacitidine for injection). The generic drug is approved for the same indications as VIDAZA®. This includes treating adults with intermediate-2 or high-risk myelodysplastic syndromes (according to the International... [Read Article]
Print Friendly, PDF & Email

Study reveals misperceptions among AML patients

Print Friendly, PDF & Email


Nurse bandaging cancer patient’s arm
Photo by Rhoda Baer
A study of acute myeloid leukemia (AML) patients has revealed misperceptions about treatment risks and the likelihood of cure. Investigators surveyed 100 AML patients receiving intensive and non-intensive chemotherapy, as well as the patients’ oncologists. The results showed that patients tended to overestimate both... [Read Article]
Print Friendly, PDF & Email

Targeting key pathways to eradicate AML

Print Friendly, PDF & Email


Lab mice
Photo by Aaron Logan
Targeting two pathways simultaneously—one critical for oncogenesis and one essential for cell survival—may be an effective strategy for treating acute myeloid leukemia (AML), according to researchers. The team studied mouse models of FLT3-ITD AML and found an inhibitor targeting the FLT3 pathway was largely effective against the disease.... [Read Article]
Print Friendly, PDF & Email

ATLG fights GVHD but reduces PFS, OS

Print Friendly, PDF & Email


Micrograph showing GVHD
Image from PLOS ONE
Results of a phase 3 trial suggest rabbit anti-T lymphocyte globulin (ATLG) can reduce graft-versus-host disease (GVHD) but also decrease survival in patients who have received a hematopoietic stem cell transplant (HSCT) from a matched, unrelated donor. In this randomized trial, ATLG significantly decreased the incidence... [Read Article]
Print Friendly, PDF & Email

Preserving normal hematopoietic function in AML

Print Friendly, PDF & Email


Red blood cells
Preclinical research has revealed a treatment that might preserve normal hematopoietic function in patients with acute myeloid leukemia (AML). Researchers found that AML suppresses adipocytes in the bone marrow, which leads to imbalanced regulation of endogenous hematopoietic stem and progenitor cells and impaired myelo-erythroid maturation. However, a PPARγ agonist can... [Read Article]
Print Friendly, PDF & Email